Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $18M (up 6.7% year over year) with net income of −$7M.
Q3 2026 key financials · XBRL
- Revenue
- $18M
- +6.7% YoY · +518.4% QoQ
- Net income
- −$7M
- +44.9% YoY · +68.8% QoQ
- Operating margin
- -50.2%
- EPS (diluted)
- −$0.26
- +46.9% YoY · +69.0% QoQ
Source: XBRL data from the Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 10-Q on SEC EDGAR. USD.
Arcturus Therapeutics Holdings Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $18.3M, up $1.1M YoY from $17.2M, driven by $16.8M CSL termination-related collaboration revenue
- Collaboration revenue $16.9M vs $14.2M; grant revenue $1.4M vs $3.0M, down 52% YoY
- Operating expenses $27.5M, down 18% YoY, including R&D $17.0M vs $23.3M
- Cash $184.8M at September 30; nine-month operating cash use $46.3M vs $58.0M
- Outlook: cash expected sufficient through at least next twelve months; additional capital anticipated, with continued losses and clinical-development spending
Risk Factors
- CSL Seqirus termination: Arcturus now funds vaccine programs without milestone payments, research funding, or profit sharing
- KOSTAIVE Japan transition: CSL Seqirus and Meiji remain responsible through June 30, 2027, creating transfer disruption risk
- myNEO acquisition: Integration requires compliance with Belgian data privacy, employment, and tax laws
- myNEO acquisition: Unregistered shares and potential milestone shares may dilute existing stockholders
- Middle East conflicts: Regional disruptions could affect international clinical sites, including Israel
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcturus Therapeutics Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.